John Ingram, MD
Neurology with Special Qualifications in Child Neurology · Jackson, MSNPI 1134319619
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,706 of the $129,807 with a category attached, or 81.4%. UCB, Inc. accounts for 73.5% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $34,671 and has fallen 69.0% since, to $10,751 in 2025.
Across 233 payments — averaging $557.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$95K
- Eisai Inc.$33K
- Livanova USA, Inc.$443
- SK Life Science, Inc.$323
- Greenwich Biosciences, Inc.$215
- PTC Therapeutics, Inc.$59
- plus $310 from 13 others
What the payments were for
- Consulting fees$9,3157%
- Speaking & faculty fees$105,70681%
- Travel & lodging$11,0278%
- Food & beverage$3,7593%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 148 | $95,434 |
| Eisai Inc. | 50 | $33,024 |
| Livanova USA, Inc. | 6 | $443 |
| SK Life Science, Inc. | 6 | $323 |
| Greenwich Biosciences, Inc. | 5 | $215 |
| PTC Therapeutics, Inc. | 3 | $59 |
| Pyros Pharmaceuticals, Inc. | 2 | $54 |
| Piramal Critical Care | 2 | $46 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Orchard Therapeutics North America | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Saol Therapeutics Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
| Medtronic | 1 | $15 |
| Catalyst Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neurology with special qualifications in child neurology providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 20 | $791 |
| Nifedipine ErNifedipine | 14 | $255 |
| Zonisamide | 14 | $220 |
| Losartan Potassium | 16 | $140 |
| Metoprolol Succinate | 14 | $52 |
| Furosemide | 12 | $18 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Jackson
- Ashley Stanley-CopelandJackson$10K
- Colette ParkerJackson$9K
- Lamar DavisJackson$4K
- Ameze EroJackson$1K
- James ThompsonJackson$808
- Matthew McGuireJackson$750
- Marcus LeeOcean Springs$68K
- Vettaikorumakankav VedanarayananMadison$33K
- Richard GormanBiloxi$35
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.